Keytruda Qlex is a new form of pembrolizumab, a cancer-fighting lab-made antibody that helps your immune system find and attack cancer cells. Unlike the original 30-minute intravenous (IV) drip, the ...

LOS ANGELES -- Patients with metastatic melanoma have faced grim prospects: the American cancer society says the five-year survival rate is only 15 percent. That started changing when the FDA approved ...

The FDA approved Merck's proposed method of administering its Keytruda cancer drug by injection rather than intravenous. Merck said Friday the injection, called Keytruda Qlex, has shown comparable ...

The company reported positive results from a trial of the heart drug that the company is counting on for much of its growth.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. BERLIN — At a prime-time session on Saturday at a major cancer conference ...

(Bloomberg) -- Merck & Co. shaved the top end of its 2025 revenue guidance and failed to produce any standout sales beats for its medicines in the third quarter, adding to challenges the drugmaker is ...

(RTTNews) - IO Biotech (IOBT), a clinical-stage biopharmaceutical company focused on cancer vaccines, Monday reported positive phase 3 results for Cylembio, in combination with Merck & Co Inc.'s (MRK) ...

A new tweak to Medicare’s drug price negotiation program will allow Merck to squeeze more revenue out of its cancer blockbuster Keytruda. The question is whether it will be enough to make a difference ...